This unique biotech$Esperion Therapeutics (ESPR.US)$Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
7
1
1
Report
10xStockPicks
OP
:
This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.
This unique biotech$Esperion Therapeutics (ESPR.US)$Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
Ultratech
:
just because it's high doesn't mean it's bearish. ppl gotta really keep their mouths shut getting tiresome of negativity from fearful users on here. after Warren buffet sold a big stake ppl were saying apple and sp500 would pull back and that simply did not happen. I don't get why ppl keep posting things that are wrong it's like nonstop everyday. it's been the same nonsense as long as i can remember naysayers have been wrong for years at some point look back at charts and see that it's been going up and think about how annoying it is how people have been saying it's going down everyday
Ultratech
72239490
OP
:
a lot of long term investors holding apple at a new ath dont want to listen to some noob crying that it's bearish. what your suggesting is obnoxious. charts are very inaccurate especially line charts nothing can predict direction is speculation
It's finally Friday, December 13th, and the market fell from a climb this morning into a light fall. Here are stories you may have missed moving markets today: $Broadcom (AVGO.US)$climbed upwards of 20%, the highest reaching percentage climber on the S&P 500 after the firm reported earnings that beat estimates Thursday, with revenue that climbed 51% from a year ago. AAI revenue for the fiscal year climbed 220%. The climb sent the stock to over $1T in ma...
Stock futures were higher premarket after markets gave back some recent gains in the previous session. Tech stocks seem to be regaining strength. Let’s see if Nasdaq can close back above the milestone level of 20,000. Meanwhile, sticky and persistent inflation could force Fed to re-consider their rate cut campaign next year. But that’s for 2025. Next week’s FOMC meeting will likely see the Fed cutting interest rate by 25 basis points again – probably setting the market up for ...
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.